386 related articles for article (PubMed ID: 32528460)
1. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
Front Immunol; 2020; 11():482. PubMed ID: 32528460
[TBL] [Abstract][Full Text] [Related]
2. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M
Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403
[TBL] [Abstract][Full Text] [Related]
3. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
4. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system.
Zhang W; Jordan KR; Schulte B; Purev E
Drug Des Devel Ther; 2018; 12():3343-3356. PubMed ID: 30323566
[TBL] [Abstract][Full Text] [Related]
5. Induction of a central memory and stem cell memory phenotype in functionally active CD4
Blaeschke F; Stenger D; Kaeuferle T; Willier S; Lotfi R; Kaiser AD; Assenmacher M; Döring M; Feucht J; Feuchtinger T
Cancer Immunol Immunother; 2018 Jul; 67(7):1053-1066. PubMed ID: 29605883
[TBL] [Abstract][Full Text] [Related]
6. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
7. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
Mock U; Nickolay L; Philip B; Cheung GW; Zhan H; Johnston ICD; Kaiser AD; Peggs K; Pule M; Thrasher AJ; Qasim W
Cytotherapy; 2016 Aug; 18(8):1002-1011. PubMed ID: 27378344
[TBL] [Abstract][Full Text] [Related]
8. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.
Jackson Z; Roe A; Sharma AA; Lopes FBTP; Talla A; Kleinsorge-Block S; Zamborsky K; Schiavone J; Manjappa S; Schauner R; Lee G; Liu R; Caimi PF; Xiong Y; Krueger W; Worden A; Kadan M; Schneider D; Orentas R; Dropulic B; Sekaly RP; de Lima M; Wald DN; Reese JS
Front Immunol; 2020; 11():1941. PubMed ID: 32849651
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
[TBL] [Abstract][Full Text] [Related]
11. Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System.
Marín Morales JM; Münch N; Peter K; Freund D; Oelschlägel U; Hölig K; Böhm T; Flach AC; Keßler J; Bonifacio E; Bornhäuser M; Fuchs A
Front Immunol; 2019; 10():38. PubMed ID: 30778344
[TBL] [Abstract][Full Text] [Related]
12. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Manufacturing Protocols Enriching T
Arcangeli S; Falcone L; Camisa B; De Girardi F; Biondi M; Giglio F; Ciceri F; Bonini C; Bondanza A; Casucci M
Front Immunol; 2020; 11():1217. PubMed ID: 32636841
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
15. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Palen K; Zurko J; Johnson BD; Hari P; Shah NN
Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
[TBL] [Abstract][Full Text] [Related]
16. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A
Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167
[TBL] [Abstract][Full Text] [Related]
17. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.
Nicod C; da Rocha MN; Warda W; Roussel X; Haderbache R; Seffar E; Trad R; Bouquet L; Goncalves M; Bosdure L; Laude MC; Guiot M; Ferrand C; Deschamps M
Curr Res Transl Med; 2023; 71(2):103385. PubMed ID: 36773434
[TBL] [Abstract][Full Text] [Related]
18. Automated, scaled, transposon-based production of CAR T cells.
Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530
[TBL] [Abstract][Full Text] [Related]
19. Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells.
Müller N; Landwehr K; Langeveld K; Stenzel J; Pouwels W; van der Hoorn MAWG; Seifried E; Bonig H
Cytotherapy; 2018 Apr; 20(4):532-542. PubMed ID: 29500069
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]